We have located links that may give you full text access.
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
Blood 2024 January 13
A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with CLL. Initial results showed that ibrutinib-containing regimens had superior PFS and rituximab did not add additional benefit. Here we present an updated analysis. With median follow-up of 55 months, median PFS was 44 months (95% CI 38-54) for BR and not yet reached in either ibrutinib-containing arm. 48-month PFS estimates were 47%, 76% and 76% for BR, ibrutinib, and IR respectively. The benefit of ibrutinib regimens over CIT was consistent across subgroups of patients defined by TP53 abnormalities, del(11q), complex karyotype, and IGHV. No significant interaction effects were observed between treatment arm and del(11q), complex karyotype, or IGHV. However, a greater difference in PFS was observed among patients with TP53 abnormalities. There remains no difference in OS. Notable adverse events with ibrutinib include atrial fibrillation (afib) and hypertension. Afib was seen in 11 pts on BR (3%) and 67 pts on ibrutinib (18%). All grade hypertension was seen in 95 pts on BR (27%) and 263 pts on ibrutinib (55%). These data show that ibrutinib regimens prolong PFS over BR for older patients with treatment-naïve CLL. These benefits are seen across subgroups, including high risk groups. Strikingly, within the ibrutinib arms, there does not appear to be inferior PFS for patients with abnormalities in TP53, the highest risk feature seen in CLL. This differentiates ibrutinib from other treatment paradigms for treatment-naïve CLL.
Full text links
Related Resources
Trending Papers
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Circulation 2024 May 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app